CEO Today Magazine May 2019 Edition 44 I N S I D E B U S I N E S S Dr. André M. Schmidt The MEDIAN Group Since 2011, Dr. André M. Schmidt has served as the CEO of the MEDIAN Hospital Group, Europe’s largest provider for post-acute and rehabilitative care. Prior to this, Dr. Schmidt worked for 6 years for McKinsey & Company and held various high level operative positions with different post-acute and nursing care provider. He studied biochemistry at Leibniz University of Hannover with a special focus on theoretical chemistry. In 1998 he received his PhD in bio- chemistry from the Technical University Darmstadt, Germany. The MEDIAN Group operates 120 rehabilitation clinics, post- acute care clinics, therapy centers, outpatient clinics and reintegration facilities with a total of 18,700 beds and treatment places. Every year, about 240,000 patients are cared for across 13 states. With a revenue of about €1 billion, MEDIAN is Europe’s largest provider of post-acute care and the fifth largest private clinic operator in Germany. MEDIAN has been disruptive in the German post-acute market through and strong focus on medical quality, bridging several levels of care (acute, post-acute/rehabilitation, sociotherapy), an aggressive growth strategy, increasing its sizes by factor 14 over the last 8 years, and a focus on Digitalisation and innovation. What are the different treatment areas that you provide at MEDIAN clinics? MEDIAN has a high level of specialist medical expertise in the fields of post-acute and rehabilitative care in the fields of neurology, cardiology, orthopedics, mental health/ psychiatry, addiction disorders, and sociotherapy. In contrast to acute clinics, it is our key goal to help patients recover and return to their social and work-life. How do you improve your science and research in order to advance your available treatments, therapies and medicines over time? The foundation of everything we do is the knowhow of our physicians, therapists and nurses. We bundle this knowhow in our Medical Boards, which come together several times a year and comprise all chief physicians in any given medical field. Our Medical Boards are the focus point, where treatment standards are developed based on external scientific evidence and the experience of our physicians. In the board meetings our physicians also have agreed on medical outcome parameters, which are collected at various points along the patient journey. Currently we are pooling the process data of therapies rendered to patients in our clinics, outcomes parameters and socio-economic data points of the patient in one single data base. Using our patient mobile app, we aim to extend the reach of our data collection process beyond the inpatient stay. The goal consists of two steps: the first is to compare our outcomes between clinics without the socio-economic bias. In the second step, we aim to use this data to develop new individualized patient pathways, that automaticity allocate a series of treatments that will deliver the best outcomes for the individual patient based on the date of 240,000 patients treated annually. In pilot projects, we are already using the data collection process to compare different treatment pathways. Our database is currently already used to conduct various studies with external partners, mostly universities, but also with our payers. Thus, we want to

RkJQdWJsaXNoZXIy Mjk3Mzkz